Determination of somatic oncogenic mutations linked to target-based therapies using MassARRAY technology.
about
PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab.Mass spectrometry-based assay for the molecular diagnosis of glioma: concomitant detection of chromosome 1p/19q codeletion, and IDH1, IDH2, and TERT mutation status.MassARRAY-based simultaneous detection of hotspot somatic mutations and recurrent fusion genes in papillary thyroid carcinoma: the PTC-MA assay.
P2860
Determination of somatic oncogenic mutations linked to target-based therapies using MassARRAY technology.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 09 March 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Determination of somatic oncog ...... es using MassARRAY technology.
@en
Determination of somatic oncog ...... es using MassARRAY technology.
@nl
type
label
Determination of somatic oncog ...... es using MassARRAY technology.
@en
Determination of somatic oncog ...... es using MassARRAY technology.
@nl
prefLabel
Determination of somatic oncog ...... es using MassARRAY technology.
@en
Determination of somatic oncog ...... es using MassARRAY technology.
@nl
P2093
P2860
P50
P356
P1433
P1476
Determination of somatic oncog ...... es using MassARRAY technology.
@en
P2093
Andrés Cervantes
Cristina Mongort
Elisa Alonso
Juan Miguel Cejalvo
Maider Ibarrola-Villava
Marta J Llorca-Cardeñosa
Octavio Burgues
Samuel Navarro
Tania Fleitas
P2860
P304
22543-22555
P356
10.18632/ONCOTARGET.8002
P407
P577
2016-03-09T00:00:00Z